Literature DB >> 15332370

[Carcinoembryonic antigen (CEA) as an independent prognostic factor in colorectal carcinoma].

Guillermo Bannura1, Miguel A Cumsille, Jaime Contreras, Alejandro Barrera, Carlos Melo, Daniel Soto.   

Abstract

BACKGROUND: CEA is widely used in the follow up of patients with colorectal carcinoma. AIM: To study the value of preoperative CEA as an independent prognostic factor in colorectal carcinoma. PATIENTS AND METHODS: Analysis of 373 operated patients (204 females, age range 21-92 years) with colorectal carcinoma and a mean follow up of 53 months. The cutoff value for CEA was 5 ng/ml. Ninety four percent of patients had an excisable tumor, 79% had involvement of perirectal/pericolonic adipose tissue and 46% had lymph node involvement. Staging was done using Dukes-Turnbull and TNM classifications.
RESULTS: CEA was normal in 61% of cases, over 5 ng/ml in 39% and over 15 ng/ml in 22%. There was a strong correlation between mean preoperative CEA and tumor stage, depth and lymph node involvement. During the follow up, 140 patients died, 57 with normal and 83 with elevated CEA. Cancer mortality in patients subjected to a curative excision of the tumor (Dukes A-C2/TNM I-III) was 9% for colonic tumors and 36% for rectal tumors (p < 0.001). There were no survival differences in patients with Dukes B/TNM II tumors according to preoperative CEA. Among Dukes C/TNM III tumors, survival difference was only significant for rectal tumors. A Cox model disclosed tumor stage, location and preoperative CEA as independent prognostic factors for survival.
CONCLUSIONS: CEA is an independent prognostic factor for survival in colorectal carcinoma and high levels suggest an advanced disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15332370     DOI: 10.4067/s0034-98872004000600005

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  7 in total

1.  Increased plasma levels of the APC-interacting protein MAPRE1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women.

Authors:  Jon J Ladd; Tina Busald; Melissa M Johnson; Qing Zhang; Sharon J Pitteri; Hong Wang; Dean E Brenner; Paul D Lampe; Raju Kucherlapati; Ziding Feng; Ross L Prentice; Samir M Hanash
Journal:  Cancer Prev Res (Phila)       Date:  2012-01-25

2.  The clinical value of von Willebrand factor in colorectal carcinomas.

Authors:  Vera S Schellerer; Larissa Mueller-Bergh; Susanne Merkel; Robert Zimmermann; Dominik Weiss; Anne Schlabrakowski; Elisabeth Naschberger; Michael Stürzl; Werner Hohenberger; Roland S Croner
Journal:  Am J Transl Res       Date:  2011-09-23       Impact factor: 4.060

Review 3.  Telomeres and telomerase in the clinical management of colorectal cancer.

Authors:  C Piñol-Felis; T Fernández-Marcelo; J Viñas-Salas; C Valls-Bautista
Journal:  Clin Transl Oncol       Date:  2016-10-19       Impact factor: 3.405

4.  Rectal adenocarcinoma: proposal for a model based on pretreatment prognostic factors.

Authors:  Fernando Cabanillas; Mariely Nieves-Plaza; Gerardo Quevedo; Ignacio A Echenique
Journal:  P R Health Sci J       Date:  2012-06       Impact factor: 0.705

5.  Carcinoma obstruction of the proximal colon cancer and long-term prognosis--obstruction is a predictor of worse outcome in TNM stage II tumor.

Authors:  Chih-Chien Chin; Jeng-Yi Wang; Chung-Rong Changchien; Wen-Shih Huang; Reiping Tang
Journal:  Int J Colorectal Dis       Date:  2010-02-05       Impact factor: 2.571

6.  Multivariate explanatory model for sporadic carcinoma of the colon in Dukes' stages I and IIa.

Authors:  J M Villadiego-Sánchez; M Ortega-Calvo; R Pino-Mejías; A Cayuela; P Iglesias-Bonilla; F García-de la Corte; J M Santos-Lozano; José Lapetra-Peralta
Journal:  Int J Med Sci       Date:  2009-01-30       Impact factor: 3.738

7.  Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment.

Authors:  Li-Chu Sun; Koung-Shing Chu; Su-Chen Cheng; Chien-Yu Lu; Chao-Hung Kuo; Jan-Sing Hsieh; Ying-Ling Shih; Shun-Jen Chang; Jaw-Yuan Wang
Journal:  BMC Cancer       Date:  2009-08-20       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.